Display options
Cite
Wang J, Zhang B, Sun J, et al. Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy. Adv Ther (Weinh). 2019;3(1)doi: 10.1002/adtp.201900083.
Wang, J., Zhang, B., Sun, J., Wang, Y., & Wang, H. (2020). Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy. Advanced therapeutics, 3(1), . https://doi.org/10.1002/adtp.201900083
Wang, Jinping, et al. "Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy." Advanced therapeutics vol. 3,1 (2020). doi: https://doi.org/10.1002/adtp.201900083
Wang J, Zhang B, Sun J, Wang Y, Wang H. Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy. Adv Ther (Weinh). 2020 Jan;3(1). doi: 10.1002/adtp.201900083. Epub 2019 Sep 30. PMID: 34277929; PMCID: PMC8281934.
Copy Download .nbib Format: NLM
Share it on

Adv Ther (Weinh). 2020 Jan;3(1). doi: 10.1002/adtp.201900083. Epub 2019 Sep 30.

Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy.

Advanced therapeutics

Jinping Wang, Beilu Zhang, Jingyu Sun, Yuhao Wang, Hongjun Wang

Affiliations

  1. Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ 07030, USA.
  2. Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ 07030, USA.
  3. Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ 07030, USA; Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ 07030, USA.

PMID: 34277929 PMCID: PMC8281934 DOI: 10.1002/adtp.201900083

Abstract

Hypoxia is a common condition of solid tumors that is mainly caused by enhanced tumor proliferative activity and dysfunctional vasculature. In the treatment of hypoxic human solid tumors, many conventional therapeutic approaches (e.g., oxygen-dependent photodynamic therapy, anticancer drug-based chemotherapy or X-ray induced radiotherapy) become considerably less effective or ineffective. In recent years, various strategies have been explored to deliver or generate oxygen inside solid tumors to overcome tumorous hypoxia and show promising evidence to improve the antitumor efficiency. In this review, the extrinsic regulation of tumor hypoxia via nanomaterial delivery is discussed followed by a summary of the mechanisms through which the modulated tumor hypoxic microenvironment improves therapeutic efficacy. The review concludes with future perspectives, to specifically address the translation of nanomaterial-based therapeutic strategies for clinical applications.

Keywords: chemotherapy; nanomedicine; photodynamic therapy; radiotherapy; tumor hypoxic microenvironment

Conflict of interest statement

Conflict of Interest The authors declare no conflict of interest.

References

  1. Theranostics. 2018 Sep 9;8(18):4898-4911 - PubMed
  2. ACS Appl Mater Interfaces. 2016 Sep 21;8(37):24331-8 - PubMed
  3. Adv Healthc Mater. 2013 Dec;2(12):1591-9 - PubMed
  4. Langmuir. 2019 Mar 19;35(11):4094-4100 - PubMed
  5. Nat Rev Cancer. 2003 Oct;3(10):721-32 - PubMed
  6. Oncol Lett. 2017 Sep;14(3):3510-3514 - PubMed
  7. Nat Commun. 2016 Feb 04;7:10437 - PubMed
  8. Artif Cells Blood Substit Immobil Biotechnol. 1995;23(3):367-80 - PubMed
  9. Theranostics. 2017 Jan 12;7(3):614-623 - PubMed
  10. Nano Lett. 2016 Oct 12;16(10):6145-6153 - PubMed
  11. Angew Chem Int Ed Engl. 2019 Apr 23;58(18):5920-5924 - PubMed
  12. ACS Nano. 2016 Sep 27;10(9):8715-22 - PubMed
  13. ACS Nano. 2017 Jul 25;11(7):7006-7018 - PubMed
  14. J Appl Physiol (1985). 2009 Apr;106(4):1444-52 - PubMed
  15. Adv Mater. 2016 Apr 13;28(14):2716-23 - PubMed
  16. Chem Soc Rev. 2016 Nov 7;45(22):6250-6269 - PubMed
  17. Radiat Res. 1992 Jun;130(3):379-83 - PubMed
  18. Sci Rep. 2016 Mar 18;6:23393 - PubMed
  19. Cancer Res. 2013 Apr 15;73(8):2412-7 - PubMed
  20. Theranostics. 2018 Jan 1;8(4):955-971 - PubMed
  21. J Cell Physiol. 2018 Mar;233(3):2019-2031 - PubMed
  22. Small. 2018 Nov;14(45):e1801694 - PubMed
  23. Drug Discov Today. 2006 Sep;11(17-18):812-8 - PubMed
  24. Small. 2018 Mar;14(12):e1703045 - PubMed
  25. J Am Chem Soc. 2016 Apr 27;138(16):5222-5 - PubMed
  26. Macromol Biosci. 2011 Jul 7;11(7):865-75 - PubMed
  27. Science. 2016 Apr 8;352(6282):175-80 - PubMed
  28. Biomaterials. 2018 Apr;162:123-131 - PubMed
  29. J Control Release. 2017 Oct 10;263:79-89 - PubMed
  30. Angew Chem Int Ed Engl. 2017 Jan 16;56(3):816-820 - PubMed
  31. Adv Mater. 2015 Oct 28;27(40):6110-7 - PubMed
  32. Biomater Sci. 2018 Aug 21;6(9):2410-2425 - PubMed
  33. Oncotarget. 2015 Jun 20;6(17):15652-61 - PubMed
  34. Biomaterials. 2018 Oct;181:310-317 - PubMed
  35. Nat Med. 2013 Nov;19(11):1423-37 - PubMed
  36. Biomaterials. 2019 Feb;192:179-188 - PubMed
  37. Acta Biomater. 2018 Oct 15;80:296-307 - PubMed
  38. Nat Chem Biol. 2015 Jan;11(1):9-15 - PubMed
  39. Blood. 2005 Jan 15;105(2):659-69 - PubMed
  40. Cancer Res. 2006 Feb 1;66(3):1664-74 - PubMed
  41. Artif Organs. 2012 Feb;36(2):170-7 - PubMed
  42. Adv Mater. 2016 Feb 10;28(6):1302-11 - PubMed
  43. J Control Release. 2014 Sep 28;190:531-41 - PubMed
  44. Adv Funct Mater. 2016 Apr 5;26(13):2185-2197 - PubMed
  45. ACS Nano. 2017 Jan 24;11(1):927-937 - PubMed
  46. Nat Med. 2001 Sep;7(9):987-9 - PubMed
  47. ACS Nano. 2018 Jan 23;12(1):651-661 - PubMed
  48. Adv Mater. 2018 Jun;30(23):e1706759 - PubMed
  49. Biomaterials. 2019 Jun;205:1-10 - PubMed
  50. Nat Rev Cancer. 2002 Jan;2(1):38-47 - PubMed
  51. Oncol Rep. 2014 Dec;32(6):2596-604 - PubMed
  52. Adv Colloid Interface Sci. 2018 Oct;260:65-84 - PubMed
  53. ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3405-3413 - PubMed
  54. Biomaterials. 1998 Aug;19(16):1529-39 - PubMed
  55. Science. 2005 Jan 7;307(5706):58-62 - PubMed
  56. Cancer Res. 2002 Jun 15;62(12):3387-94 - PubMed
  57. Nano Lett. 2018 Oct 10;18(10):6360-6368 - PubMed
  58. Annu Rev Med. 2015;66:17-29 - PubMed
  59. Adv Mater. 2015 Jul 22;27(28):4155-61 - PubMed
  60. Adv Mater. 2015 May 6;27(17):2775-82 - PubMed
  61. Adv Mater. 2019 Mar;31(11):e1805955 - PubMed
  62. Adv Mater. 2018 Mar;30(13):e1706090 - PubMed
  63. Chem Commun (Camb). 2007 Mar 14;(10):1056-8 - PubMed
  64. J Am Chem Soc. 2018 May 2;140(17):5670-5673 - PubMed
  65. Biomaterials. 2017 Jan;112:257-263 - PubMed
  66. Chem Commun (Camb). 2010 Apr 28;46(16):2736-8 - PubMed
  67. Nanoscale. 2013 Mar 7;5(5):1816-9 - PubMed
  68. Br J Cancer. 2010 Jun 29;103(1):52-60 - PubMed
  69. ACS Nano. 2017 Oct 24;11(10):10159-10174 - PubMed
  70. Nano Lett. 2008 May;8(5):1492-500 - PubMed
  71. Biomaterials. 2018 Nov;182:145-156 - PubMed
  72. Adv Mater. 2018 Aug;30(35):e1802006 - PubMed
  73. Clin Cancer Res. 2013 Dec 15;19(24):6741-50 - PubMed
  74. Cancer Metastasis Rev. 1994 Jun;13(2):139-68 - PubMed
  75. Nano Lett. 2018 Apr 11;18(4):2475-2484 - PubMed
  76. ACS Nano. 2013 Mar 26;7(3):2541-50 - PubMed
  77. J Physiol. 1910 May 11;40(3):190-224 - PubMed
  78. Artif Organs. 2010 Aug;34(8):622-34 - PubMed
  79. ACS Nano. 2018 Mar 27;12(3):2610-2622 - PubMed
  80. Cancer Treat Rev. 2003 Aug;29(4):297-307 - PubMed
  81. J Am Chem Soc. 2017 Feb 8;139(5):2035-2044 - PubMed
  82. Angew Chem Int Ed Engl. 2018 Sep 3;57(36):11522-11531 - PubMed
  83. Nanoscale. 2012 Jan 21;4(2):330-42 - PubMed
  84. J Am Chem Soc. 2015 Feb 4;137(4):1539-47 - PubMed
  85. Clin Cancer Res. 2017 May 15;23(10):2382-2390 - PubMed
  86. Nanoscale. 2013 Jan 7;5(1):416-21 - PubMed
  87. Adv Sci (Weinh). 2019 Jan 19;6(5):1801678 - PubMed
  88. Small. 2017 Oct;13(37): - PubMed
  89. Nat Commun. 2018 May 24;9(1):2053 - PubMed
  90. Nat Commun. 2015 Nov 03;6:8785 - PubMed
  91. Adv Healthc Mater. 2018 Oct;7(20):e1800525 - PubMed
  92. Theranostics. 2018 Jun 7;8(13):3584-3596 - PubMed
  93. Radiat Res. 2009 Nov;172(5):584-91 - PubMed
  94. Biomaterials. 2019 Mar;197:129-145 - PubMed
  95. ACS Nano. 2015 Nov 24;9(11):11090-101 - PubMed
  96. Biomaterials. 2017 Sep;138:13-21 - PubMed
  97. ACS Appl Mater Interfaces. 2018 Feb 28;10(8):6991-7002 - PubMed
  98. Chem Commun (Camb). 2013 Nov 25;49(91):10733-5 - PubMed
  99. Nat Rev Cancer. 2011 Jun;11(6):393-410 - PubMed
  100. ACS Nano. 2014 Apr 22;8(4):3202-12 - PubMed
  101. J Exp Biol. 2009 Nov;212(Pt 21):3387-93 - PubMed
  102. Biomaterials. 2011 Feb;32(6):1611-8 - PubMed
  103. Biomaterials. 2017 May;125:90-100 - PubMed
  104. Nanomedicine (Lond). 2012 Aug;7(8):1253-71 - PubMed
  105. ACS Nano. 2017 Dec 26;11(12):12849-12862 - PubMed
  106. ACS Nano. 2018 Dec 26;12(12):12721-12732 - PubMed
  107. Nat Commun. 2017 Oct 12;8(1):902 - PubMed
  108. ACS Nano. 2019 Apr 23;13(4):4742-4751 - PubMed
  109. Adv Mater. 2011 Dec 1;23(45):5392-7 - PubMed
  110. Trends Pharmacol Sci. 2017 Aug;38(8):669-686 - PubMed
  111. Cancer Res. 1991 Feb 1;51(3):794-8 - PubMed
  112. J Mater Chem B. 2018 Apr 21;6(15):2323-2331 - PubMed
  113. Adv Sci (Weinh). 2018 May 21;5(8):1800049 - PubMed
  114. J Mater Chem B. 2018 May 21;6(19):3145-3155 - PubMed
  115. Adv Mater. 2016 Sep;28(33):7129-36 - PubMed
  116. J Am Chem Soc. 2017 Aug 16;139(32):10992-10995 - PubMed
  117. Adv Mater. 2016 Sep;28(33):7143-8 - PubMed
  118. Cancer Res. 1999 Aug 1;59(15):3776-82 - PubMed
  119. Nanoscale. 2016 Feb 14;8(6):3739-52 - PubMed
  120. Nat Rev Cancer. 2014 Jun;14(6):430-9 - PubMed
  121. Adv Drug Deliv Rev. 2017 Sep 15;119:44-60 - PubMed
  122. ACS Nano. 2017 Feb 28;11(2):2227-2238 - PubMed

Publication Types

Grant support